Last reviewed · How we verify
Fluticasone propionate 100
Fluticasone propionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in target tissues.
Fluticasone propionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in target tissues. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Fluticasone propionate 100 |
|---|---|
| Also known as | SKP Fluticasone 100, Fluticasone 100 |
| Sponsor | SkyePharma AG |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Fluticasone propionate is a synthetic corticosteroid that exerts anti-inflammatory effects by binding to intracellular glucocorticoid receptors, leading to suppression of pro-inflammatory cytokine production, reduction of immune cell infiltration, and decreased mucus secretion. The 100 mcg formulation is typically delivered via inhalation for local pulmonary effect, minimizing systemic exposure while maximizing therapeutic benefit in airway inflammation.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
Key clinical trials
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma (PHASE3)
- Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study (PHASE4)
- The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis (NA)
- Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma (NA)
- Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations (PHASE4)
- ACTIV-6: COVID-19 Study of Repurposed Medications (PHASE3)
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone propionate 100 CI brief — competitive landscape report
- Fluticasone propionate 100 updates RSS · CI watch RSS
- SkyePharma AG portfolio CI